Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open-Label, Dose Escalation and Expansion Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Advanced Solid Tumors

Next Previous
Trial Profile

A Phase I/II, Open-Label, Dose Escalation and Expansion Study of LM-108 as a Single Agent or in Combination With Pembrolizumab in Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs LM-108 (Primary) ; Pembrolizumab (Primary)
  • Indications Gastric cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors LaNova Medicines Limited

Most Recent Events

  • 04 Jun 2024 Results of pooled analysis (NCT05199753, NCT05255484, and NCT05518045, data cutoff date December 25, 2023, n=48) assessing efficacy and safety of LM-108 in combination with an anti-PD-1 antibody in patients with gastric cancer were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
  • 08 Oct 2023 Status changed from recruiting to discontinued.
  • 04 Oct 2023 Planned End Date changed from 14 Sep 2024 to 30 Dec 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top